Ten years of rizatriptan: from development to clinical science and future directions.
The year 2008 marked the 10th anniversary since rizatriptan was first launched for the acute treatment of migraine. In this article we discuss the concepts that motivated the preclinical and clinical development of rizatriptan, the clinical evidence that has driven its use over the past decade, rizatriptan's overall contribution to the field, and future directions for research.
Hargreaves
Richard J
RJ
Merck Research Laboratories, West Point, PA, USA.
Lines
Chris R
CR
Rapoport
Alan M
AM
Ho
Tony W
TW
Sheftell
Fred D
FD
D000818:Animals; D015195:Drug Design; D004341:Drug Evaluation / Q000639:trends; D004358:Drug Therapy / Q000639:trends; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000266:history; D016032:Randomized Controlled Trials as Topic; D017366:Serotonin Receptor Agonists / Q000266:history / Q000494:pharmacology / Q000627:therapeutic use; D014230:Triazoles / Q000266:history / Q000494:pharmacology / Q000627:therapeutic use; D014363:Tryptamines / Q000266:history / Q000494:pharmacology / Q000627:therapeutic use
D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan